

Multifactorial prevention program for cardiovascular disease in primary care: hypertension status and effect on mortality

Susanna M. Kuneinen, Hannu Kautiainen, Mikael O. Ekblad and Päivi E. Korhonen © The Author(s) 2024

استاد راهنما: جناب آقای دکتر کامران محمدی (متخصص داخلی)

<mark>ارائه دهنده: فاطمه خطیب (دستیار تخصصی پزشکی اجتماعی)</mark>

INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
SUMMARY

INTRODUCTION

- Importance of Hypertension
- Morbidity and Mortality
- Increasing prevalence
 - Population growth
 - > Ageing
 - Behavioral factors
 - Unhealthy diet
 - Harmful alcohol consumption
 - Physical inactivity
 - Excess weigh

INTRODUCTION

Easy Diagnosis
Medications
Importance early detection
This Study

Prospective cohort study

Subjects

- Men and women aged 45–70 years.
- previously diagnosed CVD or diabetes were excluded.
- were performed from August 2005 to September 2007.
- The study procedures and inclusion criteria:
 - ▶ WC \geq 80 cm in women and \geq 94 cm in men.
 - BP ≥ 140/90 mmHg.
 - History of gestational diabetes or hypertension, and history of coronary heart disease, myocardial infarction, or stroke of their parents or siblings.

Appointment with the study nurse

- Completing questionnaire
- Physical examination
- Lifestyle counselling
- Highrisk subjects: were offered to have an appointment with the general practitioner (GP) of the project.

►N= 2659

Measurements BP

BMI

- METS


Laboratory tests

- Total cholesterol, HDL-C and triglycerides
- Fasting plasma glucose
- OGTT

Appointment with the general practitioner

- 2–4 months after the nurse's appointment.
- Physical examination
- Lifestyle counselling
- Antihypertensive medication was prescribed if systolic BP was ≥160 mmHg or diastolic ≥100 mmHg.

Definitions and formation of study groups
 Fig. 1 Formation of study groups.



Definitions and formation of study groups

- study groups
- Glucose metabolism disorders
 - Diabetes
 - Prediabetes
- LTPA level
 - Low
 - Moderate
 - high

- Mortality
 - Data was obtained from Statistics Finland.
 Deaths from:
 - All causes
 - Cardiovascular causes

Statistical analyses

RESULTS

- N=2659 (55% women)
- The mean age = 58 years (SD 7)
- Subjects
 - Normotensives: 1351 (51%)
 - screendetected hypertensives: 465 (17%)
 - medicated hypertensives: 843 (32%)
- Table 1: Baseline characteristics of the study participants

 Table 1. Baseline characteristics of the study participants.

		Hypertension status		P value [®] [multiple	
		Normotensive $N = 1351$	Screen-detected $N = 465$	Medicated N = 843	comparison]
	Age, mean, years (SD)	57 (7)	58 (7)	60 (7)	<0.001 [N/S, N/M, S/M]
	Females, n (%)	786 (58)	228 (49)	461 (55)	0.002 [N/S]
	Education years, mean (SD)	10.7 (2.7)	10.3 (2.6)	9.9 (2.6)	<0.001 [N/S, N/M, S/M]
	Body mass index, kg/m ² , mean (SD)	27.5 (4.4)	28.7 (4.6)	31.0 (5.5)	<0.001 [N/S, N/M, S/M]
	Waist circumference, cm, mean (SD)				
	Women	88 (12)	92 (13)	98 (14)	<0.001 [N/S, N/M, S/M]
	Men	99 (10)	101 (10)	106 (12)	<0.001 [N/S, N/M, S/M]
	Current smoking, n (%)	247 (19)	86 (19)	130 (15)	0.14
	AUDIT-score, mean (SD)	4.5 (4.7)	5.2 (5.3)	4.5 (4.9)	0.021 [N/S, N/M, S/M]
	Leisure-time physical activity level, n (%)				0.015 [N/S, S/M]
	Low	211 (16.1)	85 (18.8)	172 (21.0)	
	Moderate	660 (50.4)	226 (49.9)	408 (49.8)	
	High	438 (33.5)	142 (31.3)	240 (29.3)	
/	Blood pressure, mmHg, mean (SD)				
	Systolic	132 (15)	157 (16)	144 (18)	<0.001 [N/S, N/M, S/M]
	Diastolic	81 (8)	92 (10)	86 (10)	<0.001 [N/S, N/M, S/M]
	Plasma lipids, mmol/l, mean (SD)				
	Total cholesterol	5.41 (0.93)	5.53 (0.97)	5.27 (1.03)	<0.001 [N/S, N/M, S/M]
	HDL cholesterol	1.61 (0.47)	1.56 (0.42)	1.44 (0.40)	<0.001 [N/S, N/M, S/M]
	LDL cholesterol	3.26 (0.86)	3.35 (0.87)	3.15 (0.93)	<0.001 [N/M, S/M]
	Triglycerides	1.29 (0.72)	1.42 (0.84)	1.54 (0.71)	<0.001 [N/S, N/M, S/M]
	Plasma glucose, mmol/l, mean (SD)				
	Fasting	5.50 (1.09)	5.59 (1.05)	5.84 (1.28)	<0.001 [N/M, S/M]
	2h-glucose	6.92 (1.94)	7.47 (2.25)	8.20 (2.53)	<0.001 [N/S, N/M, S/M]
	Glucose disorder, n (%)				<0.001 [N/S, N/M, S/M]
	Prediabetes	151 (11)	68 (15)	161 (19)	
	Type 2 diabetes	75 (6)	34 (7)	115 (14)	
	Lipid-lowering medication, n (%)	72 (5)	36 (8)	227 (27)	<0.001 [N/M, S/M]

Mortality

- 31,710 person-years were followedup (median time 12.3 years).
- There were 289 (11%) deaths, 83 (29%) due to CVD.
- Unadjusted cumulative all-cause mortality over 13 years:
 - Normotensive: 9.1% (95% CI: 7.6 to 10.8)
 - screen-detected: 9.9% (95% CI: 7.4 to 13.1)
 - medicated group: 16.0% (95% CI: 13.6 to 18.8)
- Unadjusted cumulative CVD mortality over 13 years:
 - Normotensive: 2.5% (95% CI: 1.8 to 3.5)
 - screen-detected: 1.8% (95% CI: 1.0 to 3.5)
 - medicated group: 5.5% (95% CI: 4.1 to 7.3)
- Adjusted cumulative all-cause and CVD mortality:
 - Fig. 2 AND Table 2




Table 2. Competing risk regression (Fine and Gray hazards model) for the relationship between cardiovascular disease (CVD) risk factors and CVD mortality.

	CVD mortality	CVD mortality		
	sHR ^a (95%CI)	<i>p</i> value		
Hypertension status				
Medicated	1.00 (Reference)			
Normotensive	0.77 (0.45 to 1.31)	0.33		
Screen-detected	0.40 (0.19 to 0.88)	0.023		
Age	1.12 (1.07 to 1.17)	<0.001		
Male gender	2.57 (1.60 to 4.11)	<0.001		
Body mass index	1.00 (0.95 to 1.05)	0.95		
Total cholesterol	0.97 (0.73 to 1.29)	0.84		
Newly diagnosed diabetes	2.71 (1.57 to 4.69)	<0.001		
Education years	0.95 (0.86 to 1.06)	0.38		
Smoking	1.81 (1.08 to 3.03)	0.025		
Leisure-time physical activity level				
Low	1.00 (Reference)	<i>P</i> for linearity = 0.75		
Moderate	1.04 (0.56 to 1.92)			
High	1.11 (0.57 to 2.13)			

^aSubhazard ratio, competing-risks regression model was used where the rest of the causes of death were considered as competing risks.

DISCUSSION

- This study
- Previous studies
 - Low levels of awareness (up to 50%) and inadequate control of hypertension.
 - Prevalence of hypertension is estimated to be over 50% in the adult population.
 - Residual cardiovascular risk in BP-medicated individuals.
 - The impact of newly diagnosed T2D was surprisingly high.
 - without multifactorial intervention, the prognosis of newly diagnosed hypertensives has been worse than in normotensive subjects.
 - A higher risk of all-cause and CVD mortality than normotensive individuals.

DISCUSSION

- The limitation of the present study
- Strengths of the present study
- Targeted screening, lifestyle counseling, and prescription of evidence-based medication were associated with long-term CVD mortality risk.
- This study emphasizes the importance of early detection of hypertension and multifactorial intervention in a CVD-risk population



What is known about topic

- Hhypertension remains commonly undetected and undermedicated.
- Both high-risk and population-based strategies have been recommended to improve hypertension management.
- Evidence about the effectiveness of screening strategies for reducing hypertension-related morbidity and mortality is scarce.



What this study adds

- Screening for hypertension with home blood pressure monitoring is quite easy in primary care setting
- Timely multifactorial intervention seems to be effective in preventing hypertension-related mortality

